Aditya Bardia

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2024 Oct 21. Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. PMID: 39442617.
      View in: PubMed   Mentions:
    2. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clin Cancer Res. 2024 Oct 01; 30(19):4299-4309. Bardia A, Cortés J, Bidard FC, Neven P, Garcia-Sáenz J, Aftimos P, O'Shaughnessy J, Lu J, Tonini G, Scartoni S, Paoli A, Binaschi M, Wasserman T, Kaklamani V. PMID: 39087959; PMCID: PMC11443208.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Ann Oncol. 2024 Sep 21. André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL. PMID: 39313156.
      View in: PubMed   Mentions:
    4. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024 Sep 15. Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G, DESTINY-Breast06 Trial Investigators. PMID: 39282896.
      View in: PubMed   Mentions:
    5. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2024 Sep 12; JCO2400920. Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B, TROPION-Breast01 Investigators. PMID: 39265124.
      View in: PubMed   Mentions:
    6. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. J Clin Oncol. 2024 Sep 06; JCO2302733. Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Yves-Pierga J, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M. PMID: 39241211.
      View in: PubMed   Mentions:    Fields:    
    7. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol. 2024 Aug 23. Lloyd MR, Jhaveri K, Kalinsky K, Bardia A, Wander SA. PMID: 39179659.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply. Lancet. 2024 Jul 27; 404(10450):339-340. Rugo HS, Bardia A, Tolaney S. PMID: 39067902.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clin Cancer Res. 2024 Jul 15; 30(14):2917-2924. Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn J, Parsons H, Wander SA, Attaya V, Lormil B, Shellock M, Nagayama A, Bossuyt V, Isakoff SJ, Tolaney SM, Ellisen LW. PMID: 38709212; PMCID: PMC11247314.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    10. Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Jul 09; 10(1):55. Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. PMID: 38982075; PMCID: PMC11233646.
      View in: PubMed   Mentions:
    11. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat. 2024 Sep; 76:101103. Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, Carbone D, Geoerger B, Serra V, Jones RH, Ngeow J, Toska E, Stebbing J, Crasta K, Finn RS, Diana P, Vuina K, de Bruin RAM, Surana U, Bardia A, Kumar AP. PMID: 38943828.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    12. Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. J Clin Oncol. 2024 Aug 01; 42(22):2680-2690. Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, Iwata H, Rugo HS, Neven P, Kanagavel D, Cohen P, Paux G, Cartot-Cotton S, Stefanova-Urena M, Deyme L, Aouni J, Sebastien B, Bardia A. PMID: 38889373.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Jun 06; 10(1):41. Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. PMID: 38844800; PMCID: PMC11156627.
      View in: PubMed   Mentions:
    14. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clin Cancer Res. 2024 May 15; 30(10):2008-2010. Wander SA, Bardia A. PMID: 38319645.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Oncologist. 2024 May 15. Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J. PMID: 38748596.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    16. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024 Jun; 25(6):707-719. Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C, DESTINY-PanTumor01 study group. PMID: 38710187.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    17. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024; 16:17588359241248336. Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. PMID: 38686016; PMCID: PMC11057345.
      View in: PubMed   Mentions: 4  
    18. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child. Expert Rev Anticancer Ther. 2024 Jun; 24(6):397-405. Keenan JC, Medford AJ, Dai CS, Wander SA, Spring LM, Bardia A. PMID: 38642015.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    19. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Apr 25; 10(1):33. Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. PMID: 38664404; PMCID: PMC11045722.
      View in: PubMed   Mentions: 1  
    20. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 01; 42(19):2281-2294. Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F. PMID: 38652877; PMCID: PMC11210948.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    21. CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer. NEJM Evid. 2024 May; 3(5):EVIDoa2300231. Lloyd MR, Brett JO, Carmeli A, Weipert CM, Zhang N, Yu J, Bucheit L, Medford AJ, Wagle N, Bardia A, Wander SA. PMID: 38815172.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer. NPJ Breast Cancer. 2024 Apr 11; 10(1):27. Bar Y, Keenan JC, Niemierko A, Medford AJ, Isakoff SJ, Ellisen LW, Bardia A, Vidula N. PMID: 38605020; PMCID: PMC11009384.
      View in: PubMed   Mentions:
    23. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024 Jun 20; 42(18):2149-2160. Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J, acelERA Breast Cancer Study Investigators. PMID: 38537155; PMCID: PMC11185917.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    24. The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncol Pract. 2024 Jul; 20(7):972-983. Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. PMID: 38518184.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024 Mar 21; 390(12):1080-1091. Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. PMID: 38507751.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    26. Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. bioRxiv. 2024 Mar 14. Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, Kelly J, Walsh J, Nieman L, Galler I, Chan P, Lawrence MS, Sullivan RJ, Bardia A, Micalizzi DS, Sequist LV, Lee RJ, Franses JW, Ting DT, Brunker PAR, Maheswaran S, Miyamoto DT, Haber DA, Toner M. PMID: 38559183; PMCID: PMC10980012.
      View in: PubMed   Mentions:
    27. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr; 125:102720. Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. PMID: 38502995.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20; 42(15):1738-1744. Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. PMID: 38422473; PMCID: PMC11107894.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    29. Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. Clin Cancer Res. 2024 02 16; 30(4):754-766. Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García-Estévez L, López-Miranda E, Pérez-Fidalgo JA, Pérez-García JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. PMID: 37921755; PMCID: PMC10870118.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    30. Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). Breast Cancer Res Treat. 2024 Jun; 205(2):211-226. Gao L, Medford A, Spring L, Bar Y, Hu B, Jimenez R, Isakoff SJ, Bardia A, Peppercorn J. PMID: 38355821.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    31. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. Cancer Discov. 2024 Feb 08; 14(2):227-239. Varkaris A, Fece de la Cruz F, Martin EE, Norden BL, Chevalier N, Kehlmann AM, Leshchiner I, Barnes H, Ehnstrom S, Stavridi AM, Yuan X, Kim JS, Ellis H, Papatheodoridi A, Gunaydin H, Danysh BP, Parida L, Sanidas I, Ji Y, Lau K, Wulf GM, Bardia A, Spring LM, Isakoff SJ, Lennerz JK, Del Vecchio K, Pierce L, Pazolli E, Getz G, Corcoran RB, Juric D. PMID: 37916958; PMCID: PMC10850944.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative). Future Oncol. 2024 Apr; 20(11):635-651. Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Spears PA, Tolaney SM. PMID: 38270051.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Corrigendum to "Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child": [Ann Oncol 34 (2023) 968-969]. Ann Oncol. 2024 May; 35(5):481. Abelman R, Spring LM, Corcoran RB, Bardia A. PMID: 38195362.
      View in: PubMed   Mentions:    Fields:    
    34. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024 Mar; 35(3):293-301. Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. PMID: 38092228.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    35. Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clin Cancer Res. 2023 11 14; 29(22):4540-4548. Medford AJ, Moy B, Spring LM, Hurvitz SA, Turner NC, Bardia A. PMID: 37477704.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration. JCO Oncol Pract. 2024 01; 20(1):69-76. Spring LM, Mortensen L, Abraham E, Keenan J, Medford A, Ma A, Padden S, Denault E, Ryan L, Iafrate AJ, Lennerz J, Hochberg E, Wander SA, Moy B, Isakoff SJ, Juric D, Brennan KA, Smith DE, Civiello B, Mulvey T, Comander A, Ellisen LW, Schwartz JH, Bardia A. PMID: 37922440.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child. Ann Oncol. 2023 11; 34(11):968-969. Abelman R, Spring LM, Corcoran R, Bardia A. PMID: 37996170.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. Breast Cancer Res. 2023 10 02; 25(1):112. Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. PMID: 37784176; PMCID: PMC10546685.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023 11; 34(11):1003-1014. André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, Tripathy D, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. PMID: 37673211.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    40. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023 09; 24(9):1029-1041. Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Auñón P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Pérez-Moreno PD, López-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA, coopERA Breast Cancer study group. PMID: 37657462.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    41. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 10 21; 402(10411):1423-1433. Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. PMID: 37633306.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    42. Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3092-3100. Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA. PMID: 37265453.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2023 08 01; 29(15):2781-2790. Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. PMID: 37261814; PMCID: PMC10390885.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    44. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2024 Mar; 20(8):423-436. Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. PMID: 37387213.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    45. Circulating Tumor DNA in Breast Cancer: Current and Future Applications. Clin Breast Cancer. 2023 10; 23(7):687-692. Medford AJ, Denault EN, Moy B, Parsons HA, Bardia A. PMID: 37438196.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells. Breast Cancer Res Treat. 2023 Aug; 201(1):43-56. Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S. PMID: 37318638; PMCID: PMC10300156.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    47. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023 08; 34(8):645-659. Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano G. PMID: 37269905.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    48. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023; 15:17588359231178125. Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. PMID: 37275963; PMCID: PMC10233570.
      View in: PubMed   Mentions: 19  
    49. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Target Oncol. 2023 05; 18(3):313-319. Bardia A, Viale G. PMID: 37133651; PMCID: PMC10191945.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO Precis Oncol. 2023 05; 7:e2200531. Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, Cristofanilli M. PMID: 37141549; PMCID: PMC10309576.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO Precis Oncol. 2023 05; 7:e2200532. Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, Che D, Nayar U, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Ryan LY, Juric D, Moy B, Ellisen LW, Maheswaran S, Wagle N, Haber DA, Bardia A, Wander SA. PMID: 37141550; PMCID: PMC10530719.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study). Breast Cancer Res Treat. 2023 Jun; 199(3):501-509. Isakoff SJ, Said MR, Kwak AH, Glieberman E, O'Rourke EA, Stroiney A, Spring LM, Moy B, Bardia A, Horick N, Peppercorn JM. PMID: 37103597; PMCID: PMC10132949.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    53. Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. NPJ Breast Cancer. 2023 Apr 19; 9(1):29. Vidula N, Niemierko A, Hesler K, Ryan L, Moy B, Isakoff S, Ellisen L, Juric D, Bardia A. PMID: 37076495; PMCID: PMC10115848.
      View in: PubMed   Mentions:
    54. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. Oncologist. 2023 04 06; 28(4):358-363. Scarpetti L, Oturkar CC, Juric D, Shellock M, Malvarosa G, Post K, Isakoff S, Wang N, Nahed B, Oh K, Das GM, Bardia A. PMID: 36772966; PMCID: PMC10078911.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    55. Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia. N Engl J Med. 2023 Mar 16; 388(11):1032-1041. Lee AI, Heidari P, Fenves AZ, Bardia A, Ta R. PMID: 36920760; PMCID: PMC10133839.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Ther Adv Med Oncol. 2023; 15:17588359231152843. Rugo HS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SM, Cardoso F, Bardia A, Maheshwari VK, Tripathi S, Haftchenary S, Pathak P, Fasching PA. PMID: 36861085; PMCID: PMC9969464.
      View in: PubMed   Mentions: 2  
    57. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2023 Feb 17; 15(4). Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. PMID: 36831621; PMCID: PMC9954407.
      View in: PubMed   Mentions: 18  
    58. Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. Oncologist. 2023 02 08; 28(2):172-179. Brett JO, Ritterhouse LL, Newman ET, Irwin KE, Dawson M, Ryan LY, Spring LM, Rivera MN, Lennerz JK, Dias-Santagata D, Ellisen LW, Bardia A, Wander SA. PMID: 36493359; PMCID: PMC9907034.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    59. Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer. Hematol Oncol Clin North Am. 2023 02; 37(1):151-167. Abelman RO, Keenan JC, Ryan PK, Spring LM, Bardia A. PMID: 36435607.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    60. TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Ther Adv Med Oncol. 2023; 15:17588359231152844. Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, Dai CS, Gogakos T, Keenan JC, Occhiogrosso RH, Ryan P, Lennerz JK, Spring LM, Moy B, Ellisen LW, Bardia A. PMID: 36743521; PMCID: PMC9893401.
      View in: PubMed   Mentions: 2  
    61. Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. Ther Adv Med Oncol. 2023; 15:17588359221146133. McLaughlin S, Nakajima E, Bar Y, Hutchinson JA, Shin J, Moy B, Isakoff SJ, Bardia A, Kuter I, Spring LM. PMID: 36643653; PMCID: PMC9837262.
      View in: PubMed   Mentions:
    62. Reply to G.-F. Li et al, K. Altundag, and N. SG et al. J Clin Oncol. 2023 03 10; 41(8):1631-1632. Rugo HS, Bardia A, Tolaney SM. PMID: 36608309.
      View in: PubMed   Mentions:    Fields:    
    63. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol. 2023 01 01; 9(1):40-50. Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA. PMID: 36394849; PMCID: PMC9673022.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    64. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2023 Jan; 197(2):319-331. Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K. PMID: 36401732; PMCID: PMC9823088.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    65. Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer. NPJ Breast Cancer. 2022 Nov 04; 8(1):117. Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O'Shaughnessy J, Bardia A. PMID: 36333333; PMCID: PMC9636209.
      View in: PubMed   Mentions: 4  
    66. Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. Oncologist. 2022 11 03; 27(11):930-939. Dias-Santagata D, Heist RS, Bard AZ, da Silva AFL, Dagogo-Jack I, Nardi V, Ritterhouse LL, Spring LM, Jessop N, Farahani AA, Mino-Kenudson M, Allen J, Goyal L, Parikh A, Misdraji J, Shankar G, Jordan JT, Martinez-Lage M, Frosch M, Graubert T, Fathi AT, Hobbs GS, Hasserjian RP, Raje N, Abramson J, Schwartz JH, Sullivan RJ, Miller D, Hoang MP, Isakoff S, Ly A, Bouberhan S, Watkins J, Oliva E, Wirth L, Sadow PM, Faquin W, Cote GM, Hung YP, Gao X, Wu CL, Garg S, Rivera M, Le LP, John Iafrate A, Juric D, Hochberg EP, Clark J, Bardia A, Lennerz JK. PMID: 35852437; PMCID: PMC9632318.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. Cancer J. 2022 Nov-Dec 01; 28(6):423-428. Abelman RO, Medford A, Spring L, Bardia A. PMID: 36383904; PMCID: PMC9681022.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    68. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. EBioMedicine. 2022 Dec; 86:104316. Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M. PMID: 36332363; PMCID: PMC9637866.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    69. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023 01; 178:23-33. Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart MJ. PMID: 36379186; PMCID: PMC11195534.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    70. Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast Cancer Res Treat. 2022 Dec; 196(3):549-563. Loeser AL, Gao L, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Glenn L, Maues J, McGlown S, Ni A, Padron N, Lustberg M. PMID: 36198984.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    71. An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). JAMA Oncol. 2022 Sep 15. Prat A, Bardia A, Curigliano G, Hammond MEH, Loibl S, Tolaney SM, Viale G. PMID: 36107417.
      View in: PubMed   Mentions: 3     Fields:    
    72. Reply to R. Nishihara et al. J Clin Oncol. 2022 12 20; 40(36):4281-4282. Bidard FC, Kaklamani V, Bardia A. PMID: 36067449.
      View in: PubMed   Mentions:    Fields:    
    73. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022 Aug 29; 8(1):98. Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. PMID: 36038616; PMCID: PMC9424318.
      View in: PubMed   Mentions: 20  
    74. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022 10 10; 40(29):3365-3376. Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. PMID: 36027558.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    75. Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221119370. Denault E, Nakajima E, Naranbhai V, Hutchinson JA, Mortensen L, Neihoff E, Barabell C, Comander A, Juric D, Kuter I, Mulvey T, Peppercorn J, Rosenstock AS, Shin J, Vidula N, Wander SA, Moy B, Ellisen LW, Isakoff SJ, Iafrate AJ, Gainor JF, Bardia A, Spring LM. PMID: 36051470; PMCID: PMC9425892.
      View in: PubMed   Mentions: 3  
    76. Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization. Oncologist. 2022 Aug 13. Shuman AG, Aapro MS, Anderson B, Arbour K, Barata PC, Bardia A, Bruera E, Chabner BA, Chen H, Choy E, Conte P, Curigliano G, Dizon D, O'Reilly E, Tito Fojo A, Gelderblom H, Graubert TA, Gurtler JS, Hall E, Hirsch FR, Idbaih A, Ilson DH, Kelley M, La Vecchia C, Ludwig H, Moy B, Muss H, Opdam F, Pentz RD, Posner MR, Ross JS, Sacher A, Senan S, Perez de Celis ES, Tanabe KK, Vermorken JB, Wehrenberg-Klee E, Bates SE. PMID: 35962750; PMCID: PMC9438903.
      View in: PubMed   Mentions: 3     Fields:    
    77. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. Oncologist. 2022 08 05; 27(8):637-645. Bardia A, Harnden K, Mauro L, Pennisi A, Armitage M, Soliman H. PMID: 35642907; PMCID: PMC9355822.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    78. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. Clin Cancer Res. 2022 08 02; 28(15):3256-3267. Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A. PMID: 35583555; PMCID: PMC9662928.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    79. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022; 14:17588359221113694. Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. PMID: 35923930; PMCID: PMC9340905.
      View in: PubMed   Mentions: 22  
    80. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nat Commun. 2022 07 15; 13(1):4116. Bardia A, Chandarlapaty S, Linden HM, Ulaner GA, Gosselin A, Cartot-Cotton S, Cohen P, Doroumian S, Paux G, Celanovic M, Pelekanou V, Ming JE, Ternès N, Bouaboula M, Lee JS, Bauchet AL, Campone M. PMID: 35840573; PMCID: PMC9284491.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    81. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 09; 8(1):72. Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J. PMID: 35680967; PMCID: PMC9184615.
      View in: PubMed   Mentions: 21  
    82. Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. JCO Precis Oncol. 2022 06; 6:e2100428. Stamou MI, Chen C, Wander SA, Supko JG, Juric D, Bardia A, Wexler DJ. PMID: 35700410; PMCID: PMC9384915.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    83. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 10 01; 40(28):3246-3256. Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. PMID: 35584336; PMCID: PMC9553388.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCTClinical Trials
    84. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep; 195(2):127-139. O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. PMID: 35545724; PMCID: PMC9374646.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    85. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221083956. Bardia A, Cortes J, Hurvitz SA, Delaloge S, Iwata H, Shao ZM, Kanagavel D, Cohen P, Liu Q, Cartot-Cotton S, Pelekanou V, O'Shaughnessy J. PMID: 35309087; PMCID: PMC8928355.
      View in: PubMed   Mentions: 11  
    86. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022 Mar 01; 28(5):851-859. Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O'Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D. PMID: 34965945; PMCID: PMC9377723.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    87. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022 03 01; 28(5):821-830. Lloyd MR, Spring LM, Bardia A, Wander SA. PMID: 34725098.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    88. Adjuvant abemaciclib for high-risk breast cancer: the story continues. Ann Oncol. 2021 12; 32(12):1457-1459. Spring L, Matikas A, Bardia A, Foukakis T. PMID: 34815015.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. Nat Nanotechnol. 2022 01; 17(1):98-106. Saha T, Dash C, Jayabalan R, Khiste S, Kulkarni A, Kurmi K, Mondal J, Majumder PK, Bardia A, Jang HL, Sengupta S. PMID: 34795441; PMCID: PMC10071558.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansAnimalsCells
    90. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 03; 72(2):165-182. Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. PMID: 34767258.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    91. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23. Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. PMID: 34752147; PMCID: PMC8683230.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    92. New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer. Clin Adv Hematol Oncol. 2021 Nov; 19(11):723-725. Bardia A. PMID: 34807017.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    93. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954. Brastianos PK, Strickland MR, Lee EQ, Wang N, Cohen JV, Chukwueke U, Forst DA, Eichler A, Overmoyer B, Lin NU, Chen WY, Bardia A, Juric D, Dagogo-Jack I, White MD, Dietrich J, Nayyar N, Kim AE, Alvarez-Breckenridge C, Mahar M, Mora JL, Nahed BV, Jones PS, Shih HA, Gerstner ER, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. PMID: 34642329; PMCID: PMC8511104.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    94. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021 Oct 08; 7(1):134. Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. PMID: 34625570; PMCID: PMC8501074.
      View in: PubMed   Mentions: 17  
    95. Antibody drug conjugates for patients with breast cancer. Curr Probl Cancer. 2021 10; 45(5):100795. Medford A, Spring LM, Moy B, Bardia A. PMID: 34635342.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2022 02; 126(3):514-520. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. PMID: 34480094; PMCID: PMC8811064.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    97. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021 Oct 01; 17(30):3911-3924. Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA. PMID: 34467774.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    98. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precis Oncol. 2021; 5. Bardia A, Su F, Solovieff N, Im SA, Sohn J, Lee KS, Campos-Gomez S, Jung KH, Colleoni M, Vázquez RV, Franke F, Hurvitz S, Harbeck N, Chow L, Taran T, Rodriguez Lorenc K, Babbar N, Tripathy D, Lu YS. PMID: 34504990; PMCID: PMC8423397.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    99. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9). Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. PMID: 34544895; PMCID: PMC8454442.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    100. Relationship of established risk factors with breast cancer subtypes. Cancer Med. 2021 09; 10(18):6456-6467. McCarthy AM, Friebel-Klingner T, Ehsan S, He W, Welch M, Chen J, Kontos D, Domchek SM, Conant EF, Semine A, Hughes K, Bardia A, Lehman C, Armstrong K. PMID: 34464510; PMCID: PMC8446564.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    101. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021 10; 11(10):2436-2445. Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A, Ellisen LW. PMID: 34404686; PMCID: PMC8495771.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    102. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021 08 15; 23(1):85. Brett JO, Spring LM, Bardia A, Wander SA. PMID: 34392831; PMCID: PMC8365900.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    103. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103. Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, Bardia A. PMID: 34349115; PMCID: PMC8339067.
      View in: PubMed   Mentions: 16  
    104. Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. N Engl J Med. 2021 07 15; 385(3):e12. Bardia A, Hurvitz SA, Rugo HS. PMID: 34260848.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    105. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. Oncologist. 2021 10; 26(10):818-824. Mortensen L, Ordulu Z, Dagogo-Jack I, Bossuyt V, Winters L, Taghian A, Smith BL, Ellisen LW, Kiedrowski LA, Lennerz JK, Bardia A, Spring LM. PMID: 34176200; PMCID: PMC8488779.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    106. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist. 2021 10; 26(10):827-834. Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A. PMID: 34176192; PMCID: PMC8488774.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    107. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021 08; 125(5):679-686. Burris HA, Chan A, Bardia A, Thaddeus Beck J, Sohn J, Neven P, Tripathy D, Im SA, Chia S, Esteva FJ, Hart L, Zarate JP, Ridolfi A, Lorenc KR, Yardley DA. PMID: 34158598; PMCID: PMC8405616.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    108. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 09; 32(9):1148-1156. Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. PMID: 34116144.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    109. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA. Breast Cancer Res Treat. 2021 Jul; 188(1):43-52. Sundaresan TK, Dubash TD, Zheng Z, Bardia A, Wittner BS, Aceto N, Silva EJ, Fox DB, Liebers M, Kapur R, Iafrate J, Toner M, Maheswaran S, Haber DA. PMID: 34101078; PMCID: PMC8667563.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    110. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. Nat Cancer. 2021 06; 2(6):658-671. Griffiths JI, Chen J, Cosgrove PA, O'Dea A, Sharma P, Ma C, Trivedi M, Kalinsky K, Wisinski KB, O'Regan R, Makhoul I, Spring LM, Bardia A, Adler FR, Cohen AL, Chang JT, Khan QJ, Bild AH. PMID: 34712959; PMCID: PMC8547038.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    111. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 08; 26(8):e1427-e1433. Zubiri L, Rosovsky RP, Mooradian MJ, Piper-Vallillo AJ, Gainor JF, Sullivan RJ, Marte D, Boland GM, Gao X, Hochberg EP, Ryan DP, McEwen C, Mai M, Sharova T, Soumerai TE, Bardia A, Reynolds KL. PMID: 33932247; PMCID: PMC8242879.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    112. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology (Williston Park). 2021 05 13; 35(5):249-254. Nagayama A, Vidula N, Bardia A. PMID: 33983696.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    113. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist. 2021 08; 26(8):685-693. Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo AJ, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. PMID: 33856099; PMCID: PMC8251362.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    114. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487. Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. PMID: 33941592; PMCID: PMC8598376.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    115. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 04 22; 384(16):1529-1541. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators. PMID: 33882206.
      View in: PubMed   Mentions: 406     Fields:    Translation:HumansCTClinical Trials
    116. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522. Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. PMID: 33655682; PMCID: PMC8176966.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    117. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. PMID: 33761455.
      View in: PubMed   Mentions: 24     Fields:    
    118. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021 06; 32(6):746-756. Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. PMID: 33741442.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    119. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021 08 01; 27(15):4177-4185. Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. PMID: 33722897; PMCID: PMC8487593.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    120. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 04 20; 39(12):1360-1370. Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. PMID: 33513026; PMCID: PMC8078341.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    121. Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3404-3413. Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A. PMID: 33504549.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    122. Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. Oncotarget. 2021 Jan 19; 12(2):63-65. Vidula N, Ellisen LW, Bardia A. PMID: 33520111; PMCID: PMC7825638.
      View in: PubMed   Mentions: 1     Fields:    
    123. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Clin Cancer Res. 2021 03 01; 27(5):1361-1370. Jacob S, Davis AA, Gerratana L, Velimirovic M, Shah AN, Wehbe F, Katam N, Zhang Q, Flaum L, Siziopikou KP, Platanias LC, Gradishar WJ, Behdad A, Bardia A, Cristofanilli M. PMID: 33323406.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    124. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 01; 26(1):49-55. Durbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL. PMID: 33044765; PMCID: PMC7794195.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    125. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract. 2021 Dec; 27(8):1883-1890. Beyerlin K, Jimenez R, Zangardi M, Fell GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Spring LM. PMID: 33153384.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    126. Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020: commentary. Clin Adv Hematol Oncol. 2020 Nov; 18 Suppl 17(11):20-23. Bardia A. PMID: 33843926.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. A closer look at sacituzumab govitecan-hziy. Clin Adv Hematol Oncol. 2020 Nov; 18(11):715-717. Bardia A. PMID: 33406063.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    128. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262. Velimirovic M, Juric D, Niemierko A, Spring L, Vidula N, Wander SA, Medford A, Parikh A, Malvarosa G, Yuen M, Corcoran R, Moy B, Isakoff SJ, Ellisen LW, Iafrate A, Chabner B, Bardia A. PMID: 35050782.
      View in: PubMed   Mentions: 13     Fields:    
    129. Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. J Natl Compr Canc Netw. 2020 10 15; 1-9. Vidula N, Ellisen LW, Bardia A. PMID: 33075745.
      View in: PubMed   Mentions: 4     Fields:    
    130. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer. Clin Cancer Res. 2020 12 15; 26(24):6417-6428. Bardia A, Modi S, Oliveira M, Cortes J, Campone M, Ma B, Dirix L, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant TS, Lorenc KR, He W, Su F, Chavez-MacGregor M. PMID: 32998962; PMCID: PMC8489181.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    131. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020 12; 31(12):1709-1718. Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. PMID: 32946924.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    132. The Art of Oncology: COVID-19 Era. Oncologist. 2020 11; 25(11):997-1000g. Reynolds KL, Klempner SJ, Parikh A, Hochberg EP, Michaelson MD, Mooradian MJ, Lee RJ, Soumerai TE, Hobbs G, Piotrowska Z, Sykes DB, Farago AF, Bardia A, Rosovsky RP, Ryan DP. PMID: 32697887; PMCID: PMC7405267.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    133. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov; 16(31):2475-2485. Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. PMID: 32787449.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    134. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020; 12:1758835920943065. Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, Babu GK, Im YH, Chandiwana D, Gaur A, Lanoue B, Rodriguez-Lorenc K, Bardia A. PMID: 32782490; PMCID: PMC7385843.
      View in: PubMed   Mentions: 23  
    135. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med. 2020 Jul 16; 383(3):262-272. Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B. PMID: 32610007; PMCID: PMC7346678.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    136. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862. Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. PMID: 32571788; PMCID: PMC7501190.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    137. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):227-241. Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. PMID: 32417409; PMCID: PMC7646202.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    138. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920915980. Nagayama A, Vidula N, Ellisen L, Bardia A. PMID: 32426047; PMCID: PMC7222243.
      View in: PubMed   Mentions: 49  
    139. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. BMC Cancer. 2020 Apr 23; 20(1):347. McCarthy AM, Kumar NP, He W, Regan S, Welch M, Moy B, Iafrate AJ, Chan AT, Bardia A, Armstrong K. PMID: 32326897; PMCID: PMC7181475.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    140. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020 Apr; 16(12):705-715. Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P. PMID: 32223649.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    141. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020 03 07; 395(10226):817-827. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. PMID: 32145796.
      View in: PubMed   Mentions: 168     Fields:    Translation:Humans
    142. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. PMID: 32046998; PMCID: PMC7299787.
      View in: PubMed   Mentions: 276     Fields:    Translation:Humans
    143. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. PMID: 32042168; PMCID: PMC7456461.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    144. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 06 01; 26(11):2546-2555. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. PMID: 32034076.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    145. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science. 2020 03 27; 367(6485):1468-1473. Ebright RY, Lee S, Wittner BS, Niederhoffer KL, Nicholson BT, Bardia A, Truesdell S, Wiley DF, Wesley B, Li S, Mai A, Aceto N, Vincent-Jordan N, Szabolcs A, Chirn B, Kreuzer J, Comaills V, Kalinich M, Haas W, Ting DT, Toner M, Vasudevan S, Haber DA, Maheswaran S, Micalizzi DS. PMID: 32029688; PMCID: PMC7307008.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansAnimalsCells
    146. Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers. Cancer Discov. 2020 01; 10(1):86-103. Klotz R, Thomas A, Teng T, Han SM, Iriondo O, Li L, Restrepo-Vassalli S, Wang A, Izadian N, MacKay M, Moon BS, Liu KJ, Ganesan SK, Lee G, Kang DS, Walmsley CS, Pinto C, Press MF, Lu W, Lu J, Juric D, Bardia A, Hicks J, Salhia B, Attenello F, Smith AD, Yu M. PMID: 31601552; PMCID: PMC6954305.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    147. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. Cancer Discov. 2020 01; 10(1):72-85. Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA, Juric D. PMID: 31594766.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimalsCells
    148. Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. Oncologist. 2020 01; 25(1):78-86. Peppercorn J, Campbell E, Isakoff S, Horick NK, Rabin J, Quain K, Sequist LV, Bardia A, Collyar D, Hlubocky F, Mathews D. PMID: 31492767; PMCID: PMC6964122.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    149. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncol. 2019 Oct; 15(28):3209-3218. Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG. PMID: 31426673.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    150. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019 09; 20(9):1226-1238. Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. PMID: 31402321.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    151. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Oncologist. 2020 01; 25(1):e160-e169. Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW. PMID: 31395751; PMCID: PMC6964137.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    152. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. PMID: 31371343; PMCID: PMC6825550.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    153. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. PMID: 31341951; PMCID: PMC6635494.
      View in: PubMed   Mentions: 13  
    154. Comment on 'Bullous pyoderma gangrenosum secondary to underlying multiple myeloma: treated with ciclosporin'. Clin Exp Dermatol. 2019 10; 44(7):e245-e246. Mathivanan BR, Singh S, Bardia A, Nalwa A. PMID: 31162845.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    155. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019 06 13; 380(24):2382. Bardia A, Mayer IA, Kalinsky K. PMID: 31189049.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    156. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 07 25; 381(4):307-316. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. PMID: 31166679.
      View in: PubMed   Mentions: 371     Fields:    Translation:HumansCTClinical Trials
    157. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. PMID: 31235441.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    158. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat. 2019 Aug; 176(3):617-624. Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. PMID: 31079282; PMCID: PMC7082853.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    159. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncol. 2019 06; 20(6):746-748. Wander SA, Spring LM, Bardia A. PMID: 31036469.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    160. Clinical Validation of a Cell-Free DNA Gene Panel. J Mol Diagn. 2019 07; 21(4):632-645. Cheng J, Cao Y, MacLeay A, Lennerz JK, Baig A, Frazier RP, Lee J, Hu K, Pacula M, Meneses E, Robinson H, Batten JM, Brastianos PK, Heist RS, Bardia A, Le LP, Iafrate AJ. PMID: 31026600.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    161. Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(3):649-658. Daniell KM, Bardia A, Sun F, Roberts SA, Brunelle CL, Gillespie TC, Sayegh HE, Naoum GE, Juric D, Isakoff SJ, Fitzgerald DM, Taghian AG. PMID: 30919166.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    162. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019 03 26; 10(1):1373. Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. PMID: 30914635; PMCID: PMC6435685.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansAnimalsCells
    163. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019 02 26; 21(3):25. Spring LM, Wander SA, Zangardi M, Bardia A. PMID: 30806829; PMCID: PMC6573012.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    164. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. PMID: 30786188.
      View in: PubMed   Mentions: 330     Fields:    Translation:HumansCTClinical Trials
    165. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res. 2019 Feb 15; 25(4):1435. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. PMID: 30770494.
      View in: PubMed   Mentions:    Fields:    
    166. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019 02; 21(2):190-202. Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M. PMID: 30598531; PMCID: PMC6525097.
      View in: PubMed   Mentions: 244     Fields:    Translation:HumansAnimalsCells
    167. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Expert Opin Investig Drugs. 2019 Feb; 28(2):107-112. Zangardi ML, Spring LM, Nagayama A, Bardia A. PMID: 30507322.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    168. Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. N Engl J Med. 2018 Nov 15; 379(20):1946-1953. Bardia A, Hovnanian MD, Brachtel EF, Nardi V. PMID: 30428289.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    169. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. PMID: 30339520; PMCID: PMC6286162.
      View in: PubMed   Mentions: 55     Fields:    
    170. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J Clin Oncol. 2018 Sep 20; JCO2017748392. Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB. PMID: 30235087.
      View in: PubMed   Mentions: 30     Fields:    
    171. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Curr Med Res Opin. 2019 01; 35(1):73-80. Princic N, Aizer A, Tang DH, Smith DM, Johnson W, Bardia A. PMID: 30175631.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    172. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. PMID: 30220055; PMCID: PMC6235701.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    173. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov. 2018 10; 8(10):1286-1299. Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. PMID: 30104333; PMCID: PMC6170694.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    174. Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clin Cancer Res. 2018 11 01; 24(21):5206-5218. Bardia A, Hurvitz S. PMID: 29884743.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    175. Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. Clin J Oncol Nurs. 2018 06 01; 22(3):E71-E77. Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. PMID: 29781452.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    176. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 07; 19(7):904-915. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. PMID: 29804902.
      View in: PubMed   Mentions: 373     Fields:    Translation:HumansCTClinical Trials
    177. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat. 2018 Aug; 171(1):121-129. Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V. PMID: 29752687; PMCID: PMC6432628.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    178. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):111-120. Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA. PMID: 29744674; PMCID: PMC6226357.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    179. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. PMID: 29761158; PMCID: PMC5935675.
      View in: PubMed   Mentions: 68  
    180. Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clin Cancer Res. 2018 07 01; 24(13):2981-2983. Spring L, Bardia A. PMID: 29685881.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    181. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018 03 01; 29(3):640-645. Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A. PMID: 29236940.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    182. AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Mol Cancer Res. 2018 04; 16(4):720-727. Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S. PMID: 29453314; PMCID: PMC5882540.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    183. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discov. 2018 03; 8(3):336-353. Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Bese N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW. PMID: 29242214.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    184. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Target Oncol. 2017 Dec; 12(6):719-739. Nagayama A, Ellisen LW, Chabner B, Bardia A. PMID: 29116596.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    185. Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. Oncotarget. 2017 Dec 05; 8(63):106167-106168. Vidula N, Bardia A. PMID: 29290935; PMCID: PMC5739720.
      View in: PubMed   Mentions: 11     Fields:    
    186. High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. JCO Precis Oncol. 2017 Nov; 1:1-9. Frenk NE, Spring L, Muzikansky A, Vadvala HV, Gurski JM, Henderson LE, Mino-Kenudson M, Ly A, Bardia A, Finkelstein D, Engelman J, Mueller PR, Juric D, Weissleder R. PMID: 35172508.
      View in: PubMed   Mentions: 8     Fields:    
    187. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223. Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. PMID: 28982747.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    188. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Rev Clin Pharmacol. 2017 Nov; 10(11):1169-1176. Zangardi ML, Spring LM, Blouin GC, Bardia A. PMID: 28875723.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    189. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017 09 15; 23(18):5658. Tripathy D, Bardia A, Sellers WR. PMID: 28916619.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    190. AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res. 2017 Aug 01; 19(1):88. Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S. PMID: 28764807; PMCID: PMC5540189.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    191. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017 09; 22(9):1039-1048. Spring LM, Zangardi ML, Moy B, Bardia A. PMID: 28706010; PMCID: PMC5599204.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    192. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854. Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. PMID: 28558150.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    193. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20; 35(24):2790-2797. Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. PMID: 28548889.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    194. Antibody-drug conjugates in breast cancer. Clin Adv Hematol Oncol. 2017 Apr; 15(4):251-254. Bardia A. PMID: 28591100.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    195. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017 07 01; 23(13):3251-3262. Tripathy D, Bardia A, Sellers WR. PMID: 28351928; PMCID: PMC5727901.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    196. SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis? Lancet Oncol. 2017 05; 18(5):564-565. Spring L, Bardia A. PMID: 28314690.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    197. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 01; 35(19):2141-2148. Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. PMID: 28291390; PMCID: PMC5559902.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCTClinical Trials
    198. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res. 2017 Aug 01; 23(15):4035-4045. Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. PMID: 28270498; PMCID: PMC5540799.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
    199. Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). Biomed Opt Express. 2017 Feb 01; 8(2):555-569. Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA. PMID: 28270967; PMCID: PMC5330555.
      View in: PubMed   Mentions: 15  
    200. 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res. 2017 Jun 15; 23(12):3053-3060. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. PMID: 28011460; PMCID: PMC5474190.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    201. Using machine learning to parse breast pathology reports. Breast Cancer Res Treat. 2017 01; 161(2):203-211. Yala A, Barzilay R, Salama L, Griffin M, Sollender G, Bardia A, Lehman C, Buckley JM, Coopey SB, Polubriaginof F, Garber JE, Smith BL, Gadd MA, Specht MC, Gudewicz TM, Guidi AJ, Taghian A, Hughes KS. PMID: 27826755.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    202. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. PMID: 27367583; PMCID: PMC5738656.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    203. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016 09 01; 537(7618):102-106. Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DA. PMID: 27556950; PMCID: PMC5161614.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCells
    204. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist. 2016 09; 21(9):1035-40. Bardia A, Iafrate JA, Sundaresan T, Younger J, Nardi V. PMID: 27551012; PMCID: PMC5016066.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    205. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast. 2016 Aug; 28:191-8. Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. PMID: 27336726.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCellsCTClinical Trials
    206. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016 Jan; 21(113):65-74. Spring L, Bardia A, Modi S. PMID: 26896604; PMCID: PMC5477652.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    207. Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clin Proc. 2016 Jan; 91(1):71-80. Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Anderson KE, Cerhan JR. PMID: 26678006; PMCID: PMC4807132.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    208. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 01; 33(31):3621-7. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A. PMID: 26371147; PMCID: PMC4979243.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    209. Gene-Expression-Based Predictors for Breast Cancer. Ann Surg Oncol. 2015 Oct; 22(11):3418-32. Gupta A, Mutebi M, Bardia A. PMID: 26215189.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    210. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015 Jul; 12(7):685-91. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, Ting DT, Stott SL, Kapur R, Maheswaran S, Haber DA, Toner M. PMID: 25984697; PMCID: PMC4490017.
      View in: PubMed   Mentions: 276     Fields:    Translation:HumansCells
    211. Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater. 2015 Mar 04; 27(9):1593-9. Reátegui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber DA, Maheswaran S, Hammond PT, Toner M, Stott SL. PMID: 25640006; PMCID: PMC4492283.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    212. Preparation of natural three-dimensional goat kidney scaffold for the development of bioartificial organ. Indian J Nephrol. 2014 Nov; 24(6):372-5. Vishwakarma SK, Bhavani PG, Bardia A, Abkari A, Murthy GS, Venkateshwarulu J, Khan AA. PMID: 25484531; PMCID: PMC4244717.
      View in: PubMed   Mentions: 11  
    213. The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep. 2014 Sep; 6(3):146-153. Sarangi S, Mosulpuria K, Higgins MJ, Bardia A. PMID: 25431637; PMCID: PMC4242094.
      View in: PubMed   Mentions: 3  
    214. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014 Aug 28; 158(5):1110-1122. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran S. PMID: 25171411; PMCID: PMC4149753.
      View in: PubMed   Mentions: 1194     Fields:    Translation:HumansAnimalsCells
    215. Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? J Clin Oncol. 2014 Nov 01; 32(31):3470-1. Bardia A, Haber DA. PMID: 25024075.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    216. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014 Jul 11; 345(6193):216-20. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA. PMID: 25013076; PMCID: PMC4358808.
      View in: PubMed   Mentions: 436     Fields:    Translation:HumansAnimalsCells
    217. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist. 2014 Jun; 19(6):602-7. Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR. PMID: 24760710; PMCID: PMC4041671.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    218. Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmgenomics Pers Med. 2014; 7:95-105. Reynolds K, Sarangi S, Bardia A, Dizon DS. PMID: 24715764; PMCID: PMC3977457.
      View in: PubMed   Mentions: 6  
    219. Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer. 2014 Feb 01; 120(3):381-9. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk KH, Stearns V. PMID: 24375332; PMCID: PMC3946917.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    220. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6360-70. Bardia A, Baselga J. PMID: 24298066.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    221. Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. Biomed Opt Express. 2013; 4(12):2911-24. Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ. PMID: 24409390; PMCID: PMC3862147.
      View in: PubMed   Mentions: 17  
    222. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):357-61. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. PMID: 23958896; PMCID: PMC3830644.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    223. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 03; 5(179):179ra47. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M. PMID: 23552373; PMCID: PMC3760275.
      View in: PubMed   Mentions: 444     Fields:    Translation:HumansCells
    224. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 01; 339(6119):580-4. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. PMID: 23372014; PMCID: PMC3760262.
      View in: PubMed   Mentions: 1266     Fields:    Translation:HumansAnimalsCells
    225. Personalizing cardiovascular disease prevention among breast cancer survivors. Curr Opin Cardiol. 2012 Sep; 27(5):515-24. Singla A, Kumar G, Bardia A. PMID: 22874128.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    226. Trastuzumab for small HER-2+ breast cancer: small tumor, big decision. Oncologist. 2012; 17(4):508-11. Connolly RM, Bardia A. PMID: 22491004; PMCID: PMC3336832.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    227. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):907-14. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. PMID: 22042368; PMCID: PMC3582017.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    228. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med. 2011 Jul; 14(7):810-4. Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. PMID: 21554125; PMCID: PMC3118930.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    229. Spinal intradural extraosseous Ewing's sarcoma. Rare Tumors. 2011 Mar 30; 3(1):e7. Mateen FJ, Nassar A, Bardia A, Jatoi A, Haddock MG, Buckner JC, Lachance DH. PMID: 21464880; PMCID: PMC3070450.
      View in: PubMed   Mentions: 6  
    230. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011 Sep 15; 117(18):4155-65. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts SR, Bardia A, O'Connell MJ, Sargent DJ. PMID: 21365628; PMCID: PMC3111760.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    231. Body size and incident colorectal cancer: a prospective study of older women. Cancer Prev Res (Phila). 2010 Dec; 3(12):1608-20. Oxentenko AS, Bardia A, Vierkant RA, Wang AH, Anderson KE, Campbell PT, Sellers TA, Folsom AR, Cerhan JR, Limburg PJ. PMID: 20719902; PMCID: PMC3005991.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    232. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011 Feb; 126(1):149-55. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR. PMID: 20669045; PMCID: PMC2997337.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    233. Personalized tamoxifen: a step closer but miles to go. Clin Cancer Res. 2010 Sep 01; 16(17):4308-10. Bardia A, Stearns V. PMID: 20651057; PMCID: PMC2980759.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    234. Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy. Breast Cancer Res Treat. 2010 Apr; 120(2):437-9. Bardia A, Stearns V. PMID: 20162380.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    235. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. PMID: 20172363; PMCID: PMC2864519.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    236. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol. 2009 Aug; 9(4):419-26. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. PMID: 19574101; PMCID: PMC4479123.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    237. 66-year-old woman with painless vesicular lesions. Mayo Clin Proc. 2009 Jul; 84(7):639-42. Bardia A, Swanson EA, Thomas KG. PMID: 19567718; PMCID: PMC2704136.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    238. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause. 2009 May-Jun; 16(3):477-83. Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C. PMID: 19188850; PMCID: PMC3903404.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    239. Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? Colorectal Dis. 2010 Apr; 12(4):312-5. Bardia A, Greeno E, Miller R, Alberts S, Dozois E, Haddock M, Limburg P. PMID: 19250258.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    240. Relative weight at age 12 and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):374-8. Bardia A, Vachon CM, Olson JE, Vierkant RA, Wang AH, Hartmann LC, Sellers TA, Cerhan JR. PMID: 18250344; PMCID: PMC2575770.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    241. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008 Jan; 83(1):23-34. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Montori VM. PMID: 18173999.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    242. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. J Support Oncol. 2008 Jan; 6(1):27-32. Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, Silberstein PT. PMID: 18257398.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    243. Diagnosis of obesity by primary care physicians and impact on obesity management. Mayo Clin Proc. 2007 Aug; 82(8):927-32. Bardia A, Holtan SG, Slezak JM, Thompson WG. PMID: 17673060.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    244. Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer. 2008 Jan; 16(1):75-82. Thompson S, Bardia A, Tan A, Barton DL, Kottschade L, Sloan JA, Christensen B, Smith D, Loprinzi CL. PMID: 17598133.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    245. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007 Jun 06; 99(11):881-9. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR. PMID: 17551148.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    246. Publication bias for CAM trials in the highest impact factor medicine journals is partly due to geographical bias. J Clin Epidemiol. 2007 Nov; 60(11):1123-6. Sood A, Knudsen K, Sood R, Wahner-Roedler DL, Barnes SA, Bardia A, Bauer BA. PMID: 17938053.
      View in: PubMed   Mentions: 11     Fields:    
    247. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc. 2007 May; 82(5):561-6. Bardia A, Nisly NL, Zimmerman MB, Gryzlak BM, Wallace RB. PMID: 17493422; PMCID: PMC1964882.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimals
    248. Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? J Support Oncol. 2007 Apr; 5(4):195-8. Bardia A, Greeno E, Bauer BA. PMID: 17500507.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    249. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007 Apr; 82(4):490-513. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of Mayo Clinic Cancer Center. PMID: 17418079.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    250. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007 Mar; 82(3):364-80. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of the Mayo Clinic Cancer Center. PMID: 17352373.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    251. Treatment of obesity. Mayo Clin Proc. 2007 Jan; 82(1):93-101; quiz 101-2. Thompson WG, Cook DA, Clark MM, Bardia A, Levine JA. PMID: 17285790.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    252. Bizarre big belly ball: intraabdominal abscess mimicking stauffer syndrome secondary to uterine leiomyosarcoma. Eur J Gynaecol Oncol. 2007; 28(2):134-6. Bardia A, Thompson CA, Podratz KC, Okuno SH. PMID: 17479677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    253. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol. 2006 Dec 01; 24(34):5457-64. Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. PMID: 17135649.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    254. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med. 2006 Dec 11-25; 166(22):2478-83. Bardia A, Hartmann LC, Vachon CM, Vierkant RA, Wang AH, Olson JE, Sellers TA, Cerhan JR. PMID: 17159013.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    255. Images in clinical medicine. Intratracheal melanoma metastases. N Engl J Med. 2006 Sep 28; 355(13):1357. Bardia A, Rao RD. PMID: 17005953.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    256. Search strategies for retrieving complementary and alternative medicine clinical trials in oncology. Integr Cancer Ther. 2006 Sep; 5(3):202-5. Bardia A, Wahner-Roedler DL, Erwin PL, Sood A. PMID: 16880424.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    257. Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther. 2006 Jul 01; 3(4):240-6. Bardia A, Thompson S, Atherton PJ, Barton DL, Sloan JA, Kottschade LA, Christensen B, Collins M, Loprinzi CL. PMID: 18632500.
      View in: PubMed   Mentions: 5  
    258. Sex ratio in India. Lancet. 2006 May 27; 367(9524):1727-8. Bardia A, Anand K. PMID: 16731262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    259. Scarring moxibustion and religious scarification resulting in hepatitis C and hepatocellular carcinoma. Lancet. 2006 May 27; 367(9524):1790. Bardia A, Williamson EE, Bauer BA. PMID: 16731275.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    260. Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. J Clin Oncol. 2006 May 01; 24(13):e18-9. Bardia A, Loprinzi CL, Goetz MP. PMID: 16648492.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    261. Risk of multiple primary melanomas. JAMA. 2006 Apr 05; 295(13):1516. Bardia A, Pittelkow MR, Rao RD. PMID: 16595755.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    262. Mediastinal pancreatic pseudocyst with acute airway obstruction. J Gastrointest Surg. 2006 Jan; 10(1):146-50. Bardia A, Stoikes N, Wilkinson NW. PMID: 16368505.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    263. Long-term outcome in children with primary distal renal tubular acidosis. Indian Pediatr. 2005 Apr; 42(4):321-8. Bajpai A, Bagga A, Hari P, Bardia A, Mantan M. PMID: 15876593.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    264. Non-azotemic refractory rickets in Indian children. Indian Pediatr. 2005 Jan; 42(1):23-30. Bajpai A, Bardia A, Mantan M, Hari P, Bagga A. PMID: 15695854.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    265. Declining sex ratio: role of society, technology and government regulation in Faridabad district, Haryana. Natl Med J India. 2004 Jul-Aug; 17(4):207-11. Bardia A, Paul E, Kapoor SK, Anand K. PMID: 15372767.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Aditya's Networks
    Concepts (557)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (19)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California